知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

247 条记录 (耗时 0.031 秒)

    Biological activity of placental protein 13
    1.
    发明授权
    Biological activity of placental protein 13 有权
    胎盘蛋白13的生物活性

    公开(公告)号：US09168284B2

    公开(公告)日：2015-10-27

    申请号：US13994642

    申请日：2011-12-14

    申请人： Sveinbjorn Gizurarson ,  Hamutal Meiri

    发明人： Sveinbjorn Gizurarson ,  Hamutal Meiri

    IPC分类号： A61K38/17 ,  C07K14/47

    CPC分类号： A61K38/1709 ,  C07K14/4715

    摘要： The present invention relates to the biological and pharmacological effects of placental protein 13 (PP-13), an effect that may be used as a treatment and/or prevention of preeclampsia and placental insufficiencies, in pregnant female mammals, especially pregnant women. The invention relates to a method to treat female mammals with the purpose to precondition the uterine arteries and prevent and/or reverse the pathological conditions associated with placental insufficiency such as preeclampsia, HELLP and/or eclampsia.

    摘要翻译： 本发明涉及胎盘蛋白13（PP-13）的生物学和药理作用，其可用于孕妇哺乳动物，特别是孕妇中可用作治疗和/或预防先兆子痫和胎盘功能不足的作用。 本发明涉及一种治疗雌性哺乳动物的方法，目的在于预处理子宫动脉，并预防和/或逆转与胎盘功能不全相关的病态，如先兆子痫，HELLP和/或子痫。

    Sperm-Specific Cation Channel, Catsper2, and Uses Therefor
    3.
    发明申请
    Sperm-Specific Cation Channel, Catsper2, and Uses Therefor 有权
    精子特异性阳离子通道，Catsper2及其用途

    公开(公告)号：US20140363813A1

    公开(公告)日：2014-12-11

    申请号：US14249990

    申请日：2014-04-10

    申请人： CHILDREN'S MEDICAL CENTER CORPORATION

    发明人： Dejian REN ,  David CLAPHAM ,  David L. GARBERS ,  Timothy A. QUILL

    IPC分类号： G01N33/68 ,  C12Q1/68

    CPC分类号： A01K67/0278 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/03 ,  A61K35/12 ,  A61K38/00 ,  A61K38/177 ,  C07K14/4715 ,  C07K14/705 ,  C12Q1/6881 ,  G01N33/689 ,  Y10S530/852

    摘要： Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper2) are disclosed. The CatSper2 protein is shown to be specifically expressed in sperm. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper2 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper2 activity, methods of genotyping subjects with respect to CatSper2, methods of diagnosing and treating CatSper2-mediated disorders, including infertility, as well as methods of doing business related to CatSper2-mediated disorders.

    摘要翻译： 公开了与精子特异性的阳离子通道相关的核酸和蛋白质序列（CatSper2）。 显示CatSper2蛋白在精子中特异性表达。 公开了与CatSper2基因和蛋白相关的核酸，载体，转化细胞，转基因动物，多肽和抗体。 还提供了体外受精和避孕方法，鉴定CatSper2活性的调节剂的方法，关于CatSper2的受试者的基因分型方法，诊断和治疗CatSper2介导的障碍（包括不育症）的方法，以及与 CatSper2介导的疾病。

    DETECTION AND TREATMENT OF BREAST CANCER
    4.
    发明申请
    DETECTION AND TREATMENT OF BREAST CANCER 审中-公开
    乳腺癌的检测与治疗

    公开(公告)号：US20140349931A1

    公开(公告)日：2014-11-27

    申请号：US14366878

    申请日：2012-12-20

    申请人： The European Molecular Biology Laboratory ,  UCL Business PLC ,  Fahy Gurteen Laboratories Ltd.

    发明人： Jan Ellenberg ,  Beate Neumann ,  Marco Loddo ,  Gareth Williams ,  Kai Stoeber

    IPC分类号： C12Q1/68 ,  A61K38/30 ,  A61K45/06 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  A61K38/1709 ,  A61K38/1754 ,  A61K38/30 ,  A61K45/06 ,  C07K14/4715 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57415 ,  A61K2300/00

    摘要： The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease.The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

    摘要翻译： 本发明描述了用于确定乳腺前体病变将进入侵袭性乳腺癌的风险和/或患者中复发性非侵入性疾病的风险的方法，包括检测PAPPA和/或PAPPA功能的存在和/或水平 从患者获得的乳腺组织样品中的活性，其中如果PAPPA不存在或者以与对照相比减少的量存在，则存在进展为侵袭性癌症和/或风险或复发性疾病的风险。 本发明还通过恢复通过有丝分裂的正常进展，使得有丝分裂延迟的乳腺癌细胞对抗增殖剂（优选抗有丝分裂剂）的化学增敏作用。 在该实施方案中，施用第一种药物以从有丝分裂块释放乳腺癌细胞，并且依次施用影响增殖细胞的第二种药物用于癌细胞杀伤。

    PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) POLYNUCLEOTIDES
    5.
    发明申请
    PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) POLYNUCLEOTIDES 有权
    PREGNANCY相关等离子体蛋白A2（PAPP-A2）多核苷酸

    公开(公告)号：US20130095569A1

    公开(公告)日：2013-04-18

    申请号：US13625088

    申请日：2012-09-24

    申请人： Claus Oxvig ,  Michael Toft Overgaard

    发明人： Claus Oxvig ,  Michael Toft Overgaard

    IPC分类号： C07K14/47

    CPC分类号： C12N9/6489 ,  A61K38/00 ,  C07K14/4715 ,  C07K2319/21 ,  C07K2319/41 ,  C12Q1/37 ,  C12Q1/6876 ,  G01N33/689 ,  G01N2333/96486 ,  G01N2500/02

    摘要： The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

    摘要翻译： 本发明提供怀孕相关血浆蛋白A2（PAPP-A2），其核苷酸和氨基酸序列与编码PAPP-A2的核苷酸序列的反义分子，用于产生纯化的PAPP-A2的表达载体，能够特异性结合的抗体 用于检测编码PAPP-A2的核苷酸序列的PAPP-A2，杂交探针或寡核苷酸，用于表达PAPP-A2的遗传工程化宿主细胞，以及用于筛选怀孕和非怀孕患者病理的方法。 还描述了用于筛选怀孕和/或非怀孕患者中改变的局灶增生状态的方法，其包括检测PAPP-A2的水平。

    NEW ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES
    6.
    发明申请
    NEW ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES 审中-公开
    预测因子和预测因子肽的新测定

    公开(公告)号：US20120009605A1

    公开(公告)日：2012-01-12

    申请号：US13208801

    申请日：2011-08-12

    申请人： Eytan R. Barnea ,  Ruben Rene Gonzales Perez ,  Paul C. Leavis

    发明人： Eytan R. Barnea ,  Ruben Rene Gonzales Perez ,  Paul C. Leavis

    IPC分类号： G01N33/566 ,  C07K7/06 ,  C07K7/08 ,  G01N33/53

    CPC分类号： C07K7/06 ,  C07K14/4715 ,  G01N33/689 ,  G01N2333/70507

    摘要： The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

    摘要翻译： 本发明涉及用于检测PIF存在的测定方法以及使用该测定鉴定的PIF肽。 特别地，本发明涉及用于检测PIF的流式细胞术测定。 至少部分基于使用荧光标记的抗淋巴细胞和抗血小板抗体的流式细胞术在PIF存在下表现出玫瑰花结形成增加的观察。 进一步基于观察，流式细胞术证明在PIF存在下与CD2结合的单克隆抗体降低。 本发明还涉及PIF肽，当加入到Jurkat细胞培养物中时，观察到（i）减少抗CD2抗体与Jurkat细胞的结合; （ii）增加Jurkat细胞中CD2的表达; 或（iii）减少Jurkat细胞活力。 在另外的实施方案中，本发明提供了通过测定测试样品对抗CD2抗体与CD2底物的结合的影响来检测PIF的ELISA测定。

    ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF
    7.
    发明申请
    ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF 审中-公开
    ALPHA-FETOPROTEIN PEPTIDES及其用途

    公开(公告)号：US20110269692A1

    公开(公告)日：2011-11-03

    申请号：US13108923

    申请日：2011-05-16

    申请人： Thomas T. Andersen ,  James A. Bennett ,  Herbert I. Jacobson ,  Fassil B. Mesfin

    发明人： Thomas T. Andersen ,  James A. Bennett ,  Herbert I. Jacobson ,  Fassil B. Mesfin

    IPC分类号： A61K38/08 ,  A61K38/12 ,  A61P35/00

    CPC分类号： A61K38/1709 ,  A61K31/138 ,  A61K38/12 ,  A61K45/06 ,  A61K49/0002 ,  C07K14/4715 ,  C07K2319/00 ,  G01N33/57415 ,  A61K2300/00

    摘要： Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy.

    摘要翻译： 作为细胞增殖调节剂的治疗化合物，优选抑制剂。 这些调节剂含有排列成甲胎蛋白的亲水类似物的氨基酸结构。 调节剂可以是肽本身，例如像SEQ ID NO：5那样的八肽; 一个拟人的 或者可以是药学上可接受的支架的形式，例如连接有用于生物和/或化学活性的必需氨基酸结构的多环烃。 本发明的调节剂在一个方面与先前化合物的区别在于它们是口服活性的，因此不必将其注入患者体内。 组合物和方法可用于减少细胞的雌激素依赖性和雌激素非依赖性生长，以及治疗或预防癌症，如乳腺癌，脑癌，头颈癌，甲状腺癌，肺癌，结肠癌，卵巢癌 癌症，前列腺癌，子宫颈癌和皮肤癌。 治疗或预防方法可以包括与肽疗法组合使用他莫昔芬治疗。